1-anilino-8-naphthalenesulfonate and Vascular Diseases

1-anilino-8-naphthalenesulfonate has been researched along with Vascular Diseases in 7 studies

1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.

Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.

Research Excerpts

Excerpt	Relevance	Reference
"Patients with diabetic nephropathy have increased plasma triglycerides and reduced activity of hepatic lipase (HL), which hydrolyzes triglycerides."	1.33	Effect of hepatic lipase -514C->T polymorphism and its interactions with apolipoprotein C3 -482C->T and apolipoprotein E exon 4 polymorphisms on the risk of nephropathy in chinese type 2 diabetic patients. ( Baum, L; Chan, JC; Cheng, S; Lam, VK; Lindpaintner, K; Ng, MC; Poon, E; So, WY; Tomlinson, B; Wang, Y, 2005)

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (42.86)	18.7374
1990's	2 (28.57)	18.2507
2000's	1 (14.29)	29.6817
2010's	1 (14.29)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kashani Farid, MA	1
Azizi, F	1
Hedayati, M	1
Daneshpour, MS	1
Shamshiri, AR	1
Siassi, F	1
PANISSA, U	1
CALIFANO, G	1
Baum, L	1
Ng, MC	1
So, WY	1
Lam, VK	1
Wang, Y	1
Poon, E	1
Tomlinson, B	1
Cheng, S	1
Lindpaintner, K	1
Chan, JC	1
Naschitz, JE	1
Bejar, J	1
Mogilner, J	1
Misselevich, I	1
Steiner, Z	1
Eldar, S	1
Yeshurun, D	1
Boss, JH	1
Miller, JP	1
Mílcou, SM	1
Pitis, M	1
Spandonide, T	1
Chivu, V	1
Take, A	1
Popovici, D	1
Burkhardt, G	1
Gabsch, HC	1
Lantsch, H	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?[NCT03368066]			Phase 3	100 participants (Actual)	Interventional	2018-01-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants Who Died at 30 Days

Patients who died within 30 days of enrollment (NCT03368066)
Timeframe: 30 days

Intervention	Participants (Count of Participants)
Normal Adrenal Response	4
Relative Adrenal Insufficiency	4

Number of Participants Who Died at 6 Months

Patients who died within 6 months of enrollment (NCT03368066)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
Normal Adrenal Response	9
Relative Adrenal Insufficiency	15

Number of Participants Who Died at 90 Days

Patients who died within 90 days of enrollment (NCT03368066)
Timeframe: 90 days

Intervention	Participants (Count of Participants)
Normal Adrenal Response	5
Relative Adrenal Insufficiency	12

Number of Participants Who Died Within Index Hospitalization

Patients who died within the same hospitalization as enrollment (NCT03368066)
Timeframe: Within Hospitalization

Intervention	Participants (Count of Participants)
Normal Adrenal Response	1
Relative Adrenal Insufficiency	1

Number of Participants Who Received Liver Transplantation at 6 Months

Patients who received a liver transplant within 6 months of enrollment (NCT03368066)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
Normal Adrenal Response	8
Relative Adrenal Insufficiency	6

Number of Participants Who Received Liver Transplantation at 90 Days

Patients who received a liver transplant within 90 days of enrollment (NCT03368066)
Timeframe: 90 days

Intervention	Participants (Count of Participants)
Normal Adrenal Response	6
Relative Adrenal Insufficiency	5

Number of Participants With Cholesterol Esterification Deficiency

A percent quantification of serum cholesterol esterification will be measured via blood draw. Low values represent deficiency in esterification, which is a surrogate measure of lecthicin-cholesterol acetyltransferase (LCAT) enzymatic deficiency. (NCT03368066)
Timeframe: 24 hours

Intervention	Participants (Count of Participants)
Normal Adrenal Response	10
Relative Adrenal Insufficiency	11

Number of Participants With Low Free Cortisol

Patients will have their free cortisol levels measured to assess for deficiency. (NCT03368066)
Timeframe: 24 hours

Intervention	Participants (Count of Participants)
Normal Adrenal Response	6
Relative Adrenal Insufficiency	1

Number of Participants With Relative Adrenal Insufficiency (RAI)

A baseline total cortisol level will be obtained and then patients will receive a standard-dose synthetic ACTH (250mcg of Cosyntropin) stimulation test to assess for the presence of adrenal insufficiency. RAI is defined as a change in the total cortisol level in response to the stimulation test of <9mcg/dL when measured 60 minutes after the Cosyntropin is administered. (NCT03368066)
Timeframe: 24 hours

Intervention	Participants (Count of Participants)
Hospitalized Cirrhosis Patients	37

Number of Participants With Spur Cell Anemia

A peripheral blood smear will be obtained and assessed for presence of acanthocytes (spur cells). Spur cell anemia is defined as a serum hemoglobin < 10g/dL and the presence of >= 5% spur cells on blood smear. (NCT03368066)
Timeframe: 24 hours

Intervention	Participants (Count of Participants)
Normal Adrenal Response	6
Relative Adrenal Insufficiency	8

Participant Transplant-Free Survival

Transplant and Death are considered equivalent outcomes (NCT03368066)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
Normal Adrenal Response	41
Relative Adrenal Insufficiency	16

Reviews

1 review available for 1-anilino-8-naphthalenesulfonate and Vascular Diseases

Article	Year
Dyslipoproteinaemia of liver disease. Bailliere's clinical endocrinology and metabolism, 1990, Volume: 4, Issue:4 Topics: Cholestasis; Humans; Hypolipoproteinemias; Lipase; Lipoprotein-X; Lipoproteins, HDL; Lipoproteins, L	1990

Other Studies

6 other studies available for 1-anilino-8-naphthalenesulfonate and Vascular Diseases

Article	Year
Association between CETP Taq1B and LIPC -514C/T polymorphisms with the serum lipid levels in a group of Tehran's population: a cross sectional study. Lipids in health and disease, 2010, Sep-07, Volume: 9 Topics: Adult; Aged; Aged, 80 and over; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cohort Studie	2010
[Clearing factor variations after lumbar sympathetic resection: research on patients with chronic obstructive arteriopathy of an arteriosclerotic type in the legs]. Rassegna internazionale di clinica e terapia, 1959, Jul-31, Volume: 39 Topics: Leg; Lipase; Lipoprotein Lipase; Lumbosacral Region; Peripheral Vascular Diseases; Sympathectomy; Va	1959
Effect of hepatic lipase -514C->T polymorphism and its interactions with apolipoprotein C3 -482C->T and apolipoprotein E exon 4 polymorphisms on the risk of nephropathy in chinese type 2 diabetic patients. Diabetes care, 2005, Volume: 28, Issue:7 Topics: Apolipoprotein C-III; Apolipoproteins C; Case-Control Studies; Chin; Diabetes Mellitus, Type 2; Diab	2005
Acute lipase-induced panniculitis in rats with ligated veins of the hindlimb: a contribution to the role of acute panniculitis as a precursor of lipodermatosclerosis of venous disease. Journal of dermatological science, 1999, Volume: 19, Issue:1 Topics: Acute Disease; Adipose Tissue; Animals; Disease Models, Animal; Female; Femoral Vein; Hindlimb; Liga	1999
[Research on vascular diseases in aged persons with thyroid pathology]. Gerontologia clinica, 1966, Volume: 8, Issue:5 Topics: Aged; Blood Proteins; Blood Vessels; Cholesterol; Hemodynamics; Humans; Lipase; Lipids; Lipoproteins	1966
[Serum lipase determination within the scope of pancreas diagnosis]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1967, Feb-15, Volume: 22, Issue:4 Topics: Amylases; Biliary Tract Diseases; Clinical Enzyme Tests; Colorimetry; Fractures, Bone; Humans; Lipas	1967